New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:25 EDTAGN, SNY, JNJ, GSK, NVSAllergan rejected by rivals Sanofi, J&J as it looks for offers, Bloomberg says
Allergan (AGN) has so far been has so far been rejected by rival companies, which include Sanofi (SNY) and Johnson & Johnson (JNJ), as it has aims to entice firms to make a competing bid, according to Bloomberg, citing people familiar with the matter. One source said that Allergan also contacted GlaxoSmithKline (GSK) and Novartis (NVS). Reference Link
News For AGN;SNY;JNJ;GSK;NVS From The Last 14 Days
Check below for free stories on AGN;SNY;JNJ;GSK;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
05:17 EDTNVSNovartis Gilenya data confirms reducing brain shrinkage matter for MS patients
Subscribe for More Information
September 9, 2014
16:04 EDTAGNPershing Square reports 9.7% stake in Allergan, sends letter to board
Pershing Square Capital Management sent a letter to the board of Allergan that highlights several reasons why Allergan is extremely shareholder unfriendly and why now is the time for Allergan's management team to wake up. In the letter, Pershing Square said: "Since the bid was announced in April, 75% of Allergan’s shareholders have sold all or a portion of their investment including the company’s largest shareholder, which has sold its entire position. These shareholders are sending the board a message. They would not have sold if they believed that Allergan stock was worth more than current values... We note CFO Jeff Edwards recent decision to retire from the company at age 53 for family reasons, and his replacement by an investor relations executive rather than an experienced public company CFO. The notion that Allergan should execute the largest acquisition in its history led by an investor relations executive is a frightening proposition. While we respect an executive’s need to retire from a company for family reasons, Edwards exit also calls into question the company’s forward earnings guidance which shareholders expected him to execute on when the Company presented these projections on July 21st. I had expected that at some point one or more directors would have woken up and smelled the coffee. There is still time for a subset of directors to rescue their reputations by taking over leadership of this process from David Pyott and his handpicked advisors and doing what you are paid $400,000 per year to do on behalf of the company’s owners."
07:55 EDTNVSOphthotech earlier than expected Novartis payment positive, says Oppenheimer
After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.
06:42 EDTAGNLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
09:27 EDTNVSLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:48 EDTGSKGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
08:38 EDTNVSMerus Labs acquires Sintrom from Novartis
Subscribe for More Information
07:33 EDTNVSOphthotech achieves $50M milestone under ex-agreement with Novartis for Fovista
Subscribe for More Information
07:21 EDTAGNJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 7, 2014
17:15 EDTNVSNovartis presents new data on once-daily Ultibro Breezhaler
Subscribe for More Information
13:57 EDTGSKGlaxoSmithKline Ebola vaccine works in tests on monkeys, Bloomberg says
Subscribe for More Information
September 5, 2014
10:05 EDTAGN, JNJOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
08:41 EDTJNJJohnson & Johnson initiated with an Outperform at BMO Capital
Target $118.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use